NCT05492045 - A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 13, 2022

Primary Completion Date

June 14, 2024

Study Completion Date

June 14, 2024

Conditions

NSCLC

Interventions

DRUG

D-1553

D-1553 is a novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation.

DRUG

Other

Standard treatment of NSCLC.

Trial Locations (2)

200030

Shanghai Chest Hospital, Shanghai

310005

Zhejiang Cancer Hospital, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou